{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:16:13Z","timestamp":1794705373072,"version":"4.9.1"},"reference-count":166,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:10:05Z","timestamp":1784099405000},"page":"254-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer\u20142026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent"],"prefix":"10.1016","volume":"90","author":[{"given":"Philip","family":"Cornford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Epure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania Linares","family":"Espinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Matsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria De","family":"Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Stranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.013_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0010","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Edn presented at the 41st EAU Annual Congress London; 2026. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"10.1016\/j.eururo.2026.04.013_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.013_b0020","unstructured":"European Union. Prostate cancer burden in EU-27. European Commission; 2021. ecis.jrc.ec.europa.eu\/sites\/default\/files\/2023-12\/prostate_cancer_En-Nov_2021.pdf."},{"key":"10.1016\/j.eururo.2026.04.013_b0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors-A systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41391-021-00341-4","article-title":"Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men","volume":"24","author":"Huynh-Le","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the Impact study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0045","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (Impact): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2026.04.013_b0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.juro.2014.06.071","article-title":"Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries","volume":"193","author":"Haider","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-017-0695-6","article-title":"Testosterone therapy on active surveillance and following definitive treatment for prostate cancer","volume":"18","author":"Golla","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2026.04.013_b0065","volume":"ed. 8","author":"Brierley","year":"2017"},{"key":"10.1016\/j.eururo.2026.04.013_b0070","doi-asserted-by":"crossref","unstructured":"Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228\u201342.","DOI":"10.1097\/01.pas.0000173646.99337.b1"},{"key":"10.1016\/j.eururo.2026.04.013_b0075","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2026.04.013_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002063","article-title":"Improving clinical risk stratification at diagnosis in primary prostate cancer: A prognostic modelling study","volume":"13","author":"Gnanapragasam","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0085","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: A systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2026.04.013_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrurol.2013.112","article-title":"Defining the threshold for significant versus insignificant prostate cancer","volume":"10","author":"Van der Kwast","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","article-title":"Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: A systematic review and meta-analysis","volume":"3","author":"Goel","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0100","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.013_b0105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.2014.2085","article-title":"Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence","volume":"311","author":"Hayes","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.013_b0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0115","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer","volume":"84","author":"de Vos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0125","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw165","article-title":"Repeat prostate-specific antigen tests before prostate biopsy decisions","volume":"108","author":"Nordstr\u00f6m","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2026.04.013_b0130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1470-2045(22)00016-X","article-title":"Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study","volume":"23","author":"Grey","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0135","doi-asserted-by":"crossref","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","article-title":"The use of prostate specific antigen density to predict clinically significant prostate cancer","volume":"10","author":"Yusim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2026.04.013_b0140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","article-title":"Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer","volume":"76","author":"Houlahan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2025.05.020","article-title":"Prostate cancer detection in younger men: A comparative analysis of systematic and magnetic resonance imaging-targeted biopsy in the PROBASE trial","volume":"88","author":"Al-Monajjed","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0155","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2025.13722","article-title":"Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial","volume":"334","author":"Ng","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.013_b0160","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.013_b0165","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0170","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2019.06.005","article-title":"Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate?","volume":"3","author":"Exterkate","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2026.04.013_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2296","article-title":"Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study","volume":"348","author":"Carlsson","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.013_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.013_b0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2015.02.043","article-title":"Intermediate-term risk of prostate cancer is directly related to baseline prostate specific antigen: implications for reducing the burden of prostate specific antigen screening","volume":"194","author":"Gelfond","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2026.04.013_b0210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.15906","article-title":"A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy","volume":"131","author":"Kanagarajah","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0215","doi-asserted-by":"crossref","first-page":"734.e19","DOI":"10.1016\/j.urolonc.2020.03.020","article-title":"Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer","volume":"38","author":"Watts","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0220","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE trial: A multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0225","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2016.07.041","article-title":"Comparing Three Different Techniques for magnetic resonance imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus Cognitive Registration. Is there a Preferred Technique?","volume":"71","author":"Wegelin","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41585-022-00648-4","article-title":"Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway","volume":"20","author":"Barrett","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0235","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00261-023-03894-1","article-title":"Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy","volume":"48","author":"Ruan","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.eururo.2026.04.013_b0240","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41391-023-00770-3","article-title":"Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors","volume":"27","author":"Zambon","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","article-title":"Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis","volume":"40","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.04.013_b0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41391-022-00620-8","article-title":"Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling","volume":"26","author":"Noujeim","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0255","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1016\/j.clgc.2019.05.006","article-title":"Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer: systematic review and meta-analysis","volume":"17","author":"Tu","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.04.013_b0260","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12894-024-01553-1","article-title":"Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?","volume":"24","author":"J\u00e4derling","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2017.13","article-title":"Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach","volume":"20","author":"Bass","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","article-title":"Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches","volume":"104","author":"Roberts","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.013_b0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euf.2018.11.009","article-title":"Update on strategies to reduce infectious complications after prostate biopsy","volume":"5","author":"Pilatz","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.013_b0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euros.2022.01.001","article-title":"Role of prophylactic antibiotics in transperineal prostate biopsy: a systematic review and meta-analysis","volume":"37","author":"Basourakos","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.04.013_b0285","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s00345-020-03454-y","article-title":"Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy","volume":"39","author":"Ding","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0290","article-title":"Does the use of povidone iodine suppository decrease the infective complications of TRUS guided prostate biopsies? A randomized prospective study","volume":"113","author":"Shaker","year":"2020","journal-title":"QJM: Int J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0295","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/JU.0000000000000814","article-title":"Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis","volume":"204","author":"Pilatz","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0300","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.04.013_b0305","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pros.23326","article-title":"Intraductal carcinoma of the prostate on diagnostic needle biopsy predicts prostate cancer mortality: a population-based study","volume":"77","author":"Saeter","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2026.04.013_b0310","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s00345-019-03053-6","article-title":"Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery","volume":"38","author":"Ploussard","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","article-title":"Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate cancer local staging and disease risk classification","volume":"147","author":"Soeterik","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.013_b0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MOU.0000000000001288","article-title":"The prognostic role of prostate MRI in prostate cancer patients","volume":"35","author":"Zaurito","year":"2025","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0325","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2026.04.013_b0330","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers15061683","volume":"15","author":"Di Pierro","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.04.013_b0335","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0340","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.eururo.2026.04.013_b0345","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"Lecouvet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/pros.22764","article-title":"One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified \u201call-in-one\u201d imaging approach?","volume":"74","author":"Pasoglou","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2026.04.013_b0355","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.013_b0360","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","article-title":"Presurgical 68Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective Phase 3 imaging trial","volume":"84","author":"Dja\u00efleb","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0365","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.285.21.2750","article-title":"Cancer screening in elderly patients: a framework for individualized decision making","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.013_b0370","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2010.1923","article-title":"Gait speed and survival in older adults","volume":"305","author":"Studenski","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.013_b0375","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/cncr.25984","article-title":"Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates","volume":"117","author":"Groome","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.04.013_b0380","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0385","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.eururo.2026.04.013_b0390","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eururo.2026.04.013_b0395","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0400","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MOU.0000000000000157","article-title":"Observational studies and the natural history of screen-detected prostate cancer","volume":"25","author":"Albertsen","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0405","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jso.23584","article-title":"Active surveillance for clinically localized prostate cancer\u2013a systematic review","volume":"109","author":"Thomsen","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0410","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrurol.2017.26","article-title":"Expert consensus document: semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure","volume":"14","author":"Bruinsma","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0415","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0420","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JU.0000000000000693","article-title":"The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies","volume":"203","author":"Amin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0425","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0430","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0435","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0440","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/JU.0000000000000526","article-title":"Diagnostic accuracy of prostate biopsy for detecting cribriform Gleason Pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance","volume":"203","author":"Ericson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0445","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.juro.2015.04.113","article-title":"Baseline perineural invasion is associated with shorter time to progression in men with prostate cancer undergoing active surveillance: results from the REDEEM study","volume":"194","author":"Moreira","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0450","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41391-021-00373-w","article-title":"Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models","volume":"24","author":"Stavrinides","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0455","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-018-2420-6","article-title":"Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study","volume":"37","author":"Olivier","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0460","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JU.0000000000001339","article-title":"The clinical significance of multiple negative surveillance prostate biopsies for men on active surveillance-does cancer vanish or simply hide?","volume":"205","author":"Chu","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0465","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bju.16666","article-title":"The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer","volume":"135","author":"Gnanapragasam","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0470","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euo.2020.09.004","article-title":"Changes in magnetic resonance imaging using the prostate cancer radiologic estimation of change in sequential evaluation criteria to detect prostate cancer progression for men on active surveillance","volume":"4","author":"O'Connor","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0475","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","article-title":"Best current practice and research priorities in active surveillance for prostate cancer-A report of a Movember international consensus meeting","volume":"6","author":"Moore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0480","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMc2406108","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"391","author":"Holmberg","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0485","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0490","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/jclinpath-2014-202767","article-title":"Prostate biopsy concordance in a large population-based sample: a surveillance, epidemiology and end results study","volume":"68","author":"Schreiber","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.eururo.2026.04.013_b0495","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","article-title":"Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy","volume":"53","author":"Yossepowitch","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0500","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0505","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2016.06.023","article-title":"Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis","volume":"71","author":"Mungovan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0510","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.euf.2022.01.015","article-title":"Value of different magnetic resonance imaging-based measurements of anatomical structures on preoperative prostate imaging in predicting urinary continence after radical prostatectomy in men with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"van Dijk-de Haan","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.013_b0515","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00330-022-09320-2","article-title":"A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement","volume":"33","author":"Veerman","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.04.013_b0520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2016.01.026","article-title":"A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update","volume":"70","author":"Walz","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0525","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bco2.115","article-title":"Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy","volume":"3","author":"Vis","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2026.04.013_b0530","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0535","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.euo.2024.12.008","article-title":"Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during radical prostatectomy: a systematic review and meta-analysis","volume":"8","author":"Kroon","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0540","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(25)00091-9","article-title":"Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial","volume":"26","author":"Dinneen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0545","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0550","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective Phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0555","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/JS9.0000000000000997","article-title":"A comparative analysis of perioperative complications and biochemical recurrence between standard and extended pelvic lymph node dissection in prostate cancer patients undergoing radical prostatectomy: a systematic review and meta-analysis","volume":"110","author":"Ding","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.eururo.2026.04.013_b0560","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0565","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.013_b0570","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.euo.2021.02.001","article-title":"Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis","volume":"4","author":"Cacciamani","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0575","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00345-025-05518-3","article-title":"Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial","volume":"43","author":"Pose","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0580","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.3390\/jcm12123979","article-title":"Venous thromboembolism (VTE) in post-prostatectomy patients: systematic review and meta-analysis","volume":"12","author":"Wani","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0585","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.3390\/cancers14225667","article-title":"The prevalence of lower limb and Genital lymphedema after prostate cancer treatment: a systematic review","volume":"14","author":"Clinckaert","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.04.013_b0590","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.013_b0595","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0600","article-title":"The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures","volume":"11","author":"Yu","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.eururo.2026.04.013_b0605","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0610","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized Phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0615","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0620","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0625","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a Phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0630","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0635","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","article-title":"Magnetic resonance imaging-guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Poon","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0640","article-title":"Hypofractionation for clinically localized prostate cancer","volume":"9","author":"Hickey","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.013_b0645","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (Hydra): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0650","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.013_b0655","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0660","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41391-025-00961-0","article-title":"Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer-a systematic review and meta-analysis","volume":"28","author":"Wong","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.013_b0665","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0670","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a Phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0675","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.013_b0680","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0685","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0690","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brachy.2005.12.002","article-title":"Relationship of the international prostate symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","volume":"5","author":"Martens","year":"2006","journal-title":"Brachytherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.eururo.2026.04.013_b0695","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/jcb.2020.92913","article-title":"A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial","volume":"12","author":"Salembier","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.eururo.2026.04.013_b0705","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0710","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0715","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0720","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/02841860600710913","article-title":"3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey","volume":"45","author":"Vordermark","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0725","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijrobp.2020.11.023","article-title":"Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study","volume":"109","author":"Parry","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2026.04.013_b0735","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.euf.2020.12.016","article-title":"Oncological long-term outcome after whole-gland high-intensity focused ultrasound for prostate Cancer-21-yr follow-up","volume":"8","author":"Br\u00fcndl","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.013_b0740","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.eururo.2016.02.054","article-title":"Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort","volume":"70","author":"Dickinson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0745","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0750","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0755","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0760","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2010.03.001","article-title":"Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng\/ml: a European multi-institutional study of 712 patients","volume":"58","author":"Spahn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0770","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1464-410X.2005.05394.x","article-title":"Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome","volume":"95","author":"Ward","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0775","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0780","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.juro.2013.04.073","article-title":"Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy","volume":"190","author":"Ploussard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0785","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijrobp.2014.09.039","article-title":"Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96\u201302 trial","volume":"91","author":"Wiegel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0790","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.eururo.2017.11.024","article-title":"Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy","volume":"74","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0795","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0800","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijrobp.2008.11.007","article-title":"Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and\/or positive surgical margins","volume":"75","author":"Choo","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.013_b0805","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-013-1214-0","article-title":"Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study","volume":"32","author":"Ploussard","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0810","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0815","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.013_b0820","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bju.14241","article-title":"Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit","volume":"123","author":"Gupta","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.013_b0825","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.013_b0830","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:26:41Z","timestamp":1788740801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":166,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0302283826021147"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer\u20142026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}